Investor Presentation • May 15, 2025
Investor Presentation
Open in ViewerOpens in native device viewer


1Q 2025 Presentation
15 May 2025
















| Income statement | ||||
|---|---|---|---|---|
| Q1 25 | Q1 24 | FY 24 | ||
| Total revenue | 34 484 | 17 189 | 48 890 | |
| Cost of goods sold | 17 721 | 9 969 | 34 877 | |
| Salaries and personnel expenses | 3 653 | 3 803 | 16 753 | |
| Other operating expenses | 2 079 | 2 699 | 8 793 | |
| Total operating expenses | 23 454 | 16 471 | 60 423 | |
| Operating result (EBITDA) | 11 031 | 718 | -11 533 | |
| Depreciation | 3 000 | 3 000 | 12 693 | |
| Operating result (EBIT) | 8 031 | -2 282 | -24 225 | |
| Net interest expenses | -2 333 | -1 523 | -7 035 | |
| Net agio | -31 | -26 | 19 | |
| Net financial items | -2 364 | -1 549 | -7 016 | |
| Result before tax | 5 666 | -3 831 | -31 241 | |
| Tax expense | - | - | - | |
| Result for the period | 5 666 | -3 831 | -31 241 | |
| Assets | |||
|---|---|---|---|
| 31.03.2025 | 31.03.2024 | 31.12.2024 | |
| ASSETS | |||
| Total tangible fixed assets | 244 982 | 233 243 | 242 805 |
| Total non-current assets | 244 982 | 233 243 | 242 805 |
| Biological assets | 9 557 | 8 508 | 18 539 |
| Other inventories | 3 604 | 1 564 | 3 073 |
| Account receivables | 9 693 | 6 314 | 1 405 |
| Other receivables | 669 | 1 068 | 1 186 |
| Cash and cash equivalents | 10 134 | 17 884 | 3 236 |
| Total current assets | 33 658 | 35 338 | 27 438 |
| TOTAL ASSETS | 278 640 | 268 581 | 270 244 |
| Equity and debt | |||
|---|---|---|---|
| 31.03.2025 | 31.03.2024 | 31.12.2024 | |
| EQUITY AND LIABILITIES | |||
| Paid in equity | |||
| Paid-in equity | 188 028 | 226 844 | 186 237 |
| Earned equity | 5 666 | -21 210 | - |
| Total equity | 193 694 | 205 634 | 186 237 |
| Long term debt | |||
| Loans from credit institutions | 48 000 | 51 000 | 49 000 |
| Total other long term debt | 48 000 | 51 000 | 49 000 |
| Short term debt | |||
| Bank overdraft | 20 950 | - | 21 550 |
| Account payables | 11 909 | 8 654 | 8 698 |
| Public duties | 393 | 1 609 | 908 |
| Other short-term liabilities | 3 694 | 1 684 | 3 851 |
| Total short-term debt | 36 946 | 11 947 | 35 007 |
| Total debt | 84 946 | 62 947 | 84 007 |
| 278 640 | 268 581 | 270 244 |
| Statement of cash flows | |||
|---|---|---|---|
| Q1 25 | Q1 24 | FY 24 | |
| Cash flows from operating activities | |||
| Result before tax | 5 683 | - 3 831 - |
31 241 |
| Depreciation | 3 000 | 3 000 | 12 693 |
| Change in inventory and biological assets | 8 451 | 2 412 | - 9 128 |
| Change in account receivables | - 8 288 |
- 6 314 |
- 1 405 |
| Change in account payables | 3 211 | - 599 |
- 555 |
| Other accruals | - 175 |
11 114 | 12 149 |
| Net cash flows from operating activities | 11 882 | 5 782 - |
17 488 |
| Cash flows from investing activities | |||
| Net investment in fixed assets | - 5 177 |
- 2 697 - |
13 402 |
| Net cash flows from investing activities | - 5 177 |
- 2 697 - |
13 402 |
| Cash flows from financing activities | |||
| Repayment of long term debt | - 1 000 |
- 1 000 |
- 3 000 |
| Change in bank overdraft | - 600 |
- | 21 550 |
| New equity | 1 793 | 14 518 | 14 295 |
| Net cash flows from financing activities | 193 | 13 518 | 32 845 |
| Net cash flows for the period | 6 898 | 16 603 | 1 955 |
| Cash at the beginning of period | 3 236 | 1 281 | 1 281 |


Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.